Satiety induction

Satiety induction is a complex physiological process characterized by the feeling of fullness and the subsequent suppression of appetite following food consumption. It is not a single molecular target but rather a multi-faceted pharmacological outcome or biological state mediated by an intricate network of hormones and neural pathways (Source: StatPearls, NBK551568). The primary biological drivers of this process include peripheral hormones like Cholecystokinin (CCK), Peptide YY (PYY), and Glucagon-like peptide 1 (GLP-1), which transmit signals to the central nervous system, specifically the arcuate nucleus of the hypothalamus and the nucleus tractus solitarius in the brainstem (Source: NIH, PMC4105387). In the context of metabolic disease, satiety induction is the primary therapeutic goal for managing obesity and type 2 diabetes. Modern anti-obesity medications, such as GLP-1 receptor agonists (e.g., semaglutide), effectively induce satiety by mimicking endogenous incretins to enhance fullness and delay gastric emptying. While 'Satiety induction' itself is a physiological effect rather than a discrete protein or enzyme, targeting the underlying receptors involved in this process remains a cornerstone of drug development for weight management and metabolic health (Source: PubMed, PMID: 33571172).

Other names

Appetite suppressionFullness signalingPostprandial satietyHypophagia induction

Satiety induction is achieved via the activation of multiple signaling pathways, primarily the Glucagon-like peptide 1 receptor (GLP-1R) and the Melanocortin 4 receptor (MC4R) in the hypothalamus and brainstem, which decrease hunger signals and increase the sensation of fullness (Source: PubMed, PMID: 28319522).